Table 1 Patient baseline demographics and clinical characteristics a
Patient characteristics, N = 39 | Mean ± SD or n (%) | Median (IQR) |
|---|---|---|
Age, yr | 54.8 ± 13.3 | 56 (44 to 63) |
Female, n (%) | 35 (89.7) | – |
Disease duration, yr | 4.7 ± 3.3 | 4.5 (1.7 to 8.0) |
SJC (range, 0 to 28) | 5.8 ± 3.8 | 5 (3 to 7) |
TJC (range, 0 to 28) | 5.0 ± 3.5 | 4 (3 to 6) |
Pt-VAS (score/100 mm) | 46.2 ± 24.5 | 45 (30 to 63) |
D-VAS (score/100 mm) | 42.3 ± 16.7 | 39 (32 to 54) |
CDAI score | 19.6 ± 9.3 | 17.5 (12.0 to 25.2) |
SDAI score | 21.1 ± 9.9 | 19.8 (13.4 to 26.9) |
HAQ-DI score | 1.0 ± 0.7 | 1 (0.5 to 1.5) |
CRP, mg/dl | 1.4 ± 1.6 | 0.7 (0.2 to 2.2) |
ESR, mm/h | 48.1 ± 32.0 | 46 (19 to 68) |
MMP-3, ng/ml | 158.5 ± 147.7 | 100.2 (60.0 to 221.0) |
RF-positive, n (%) | 33 (84.6) | – |
ACPA-positive, n (%) | 33 (84.6) | – |
Concomitant methotrexate, n (%), dose,b mg/wk | 12 (30.8), 8.0 ± 1.2 | –, 8.0 (7.6 to 8.0) |
Concomitant glucocorticoid, n (%), dose,b mg/day | 10 (25.6), 5.1 ± 2.8 | –, 5 (3 to 5) |